IP Library Granted Patent US 7,396,822
Granted Patent B2
US 7,396,822 · App. 10/832,000 · Granted Jul 8, 2008

Immunogenic minicells and methods of use

Assignee: Vaxiion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,396,822
App. No.
10/832,000
Granted
Jul 8, 2008
Kind
B2
Abstract

The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

Claims (25)

1. A method of generating an immunogenic response in a subject comprising, introducing a minicell to a subject, wherein said minicell comprises a plasmid having an open reading frame encoding an antigen of interest, and a eukaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in the subject.

2. The method of claim 1 , wherein said eukaryotic expression sequence comprises a Cytomegalovirus (CMV) promoter.

3. The method of claim 1 , wherein said open reading frame is from the genome of a pathogen.

4. The method of claim 3 , wherein said pathogen is a virus.

5. The method of claim 3 , wherein said pathogen is a bacterium.

6. The method of claim 5 , wherein said bacterium is Bacillus anthracis.

7. The method of claim 1 , wherein said open reading frame encodes an antigen characteristic of a cancerous cell.

8. The method of claim 1 , wherein said plasmid further comprises a prokaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in the minicell and in the subject.

9. The method of claim 8 , wherein said antigen of interest expressed in the minicell is displayed on the surface of the minicell.

10. The method of claim 8 , wherein said eukaryotic expression sequence comprises a CMV promoter.

11. The method of claim 8 , wherein said open reading frame is from the genome of a pathogen.

12. The method of claim 11 , wherein said pathogen is a virus.

13. The method of claim 11 , wherein said pathogen is a bacterium.

14. The method of claim 13 , wherein said bacterium is Bacillus anthracis.

15. The method of claim 8 , wherein said open reading frame encodes an antigen characteristic of a cancerous cell.

16. A method of generating an immunogenic response in a subject comprising, introducing a minicell to a subject, wherein said minicell comprises first and second open reading frames, encoding first and second antigens respectively, and a eukaryotic expression sequence operably linked to said first open reading frame and a prokaryotic expression sequence operably linked to said second open reading frame, such that said first antigen is expressed in the subject, and said second antigen is expressed in the minicell.

17. The method of claim 16 , wherein said first and second open reading frames are located in a plasmid.

18. The method of claim 17 , wherein said first and second open reading frames are located in the same plasmid.

19. The method of claim 16 , wherein said eukaryotic expression sequence comprises a CMV promoter.

20. The method of claim 16 , wherein said first open reading frame is from the genome of a pathogen.

21. The method of claim 20 , wherein said pathogen is a virus.

22. The method of claim 20 , wherein said pathogen is a bacterium.

23. The method of claim 22 , wherein said bacterium is Bacillus anthracis.

24. The method of claim 16 , wherein said first open reading frame encodes an antigen characteristic of a cancerous cell.

25. The method of claim 16 , wherein said second antigen is displayed on the surface of the minicell.

Assignments (6)
ORGANIZATION CONVERSION Recorded Apr 30, 2015
From: VAXIION THERAPEUTICS, INC.
To: VAXIION THERAPEUTICS, LLC
Reel/Frame 035557/0644 →
SECURITY AGREEMENT Recorded Mar 21, 2013
From: VAXIION THERAPEUTICS INC.
To: WESTERN STATES INVESTMENT COMPANY, LLC
Reel/Frame 030062/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2012
From: GIACALONE, MATTHEW J
To: VAXIION THERAPEUTICS, INC.
Reel/Frame 027726/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2008
From: SURBER, MARK
To: VAXIION THERAPEUTICS, INC.
Reel/Frame 020559/0568 →
CHANGE OF NAME Recorded May 18, 2006
From: MPEX PHARMACEUTICALS, INC.
To: VAXIION THERAPEUTICS, INC.
Reel/Frame 017647/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2004
From: SABBADINI, ROGER A.; BERKLEY, NEIL
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 015075/0397 →
Continuity (4)
Continuation In Part 1015495100 · May 24, 2002
Provisional Application 6035984300 · Feb 25, 2002
Provisional Application 6029356600 · May 24, 2001
Related Publication 20050147590A1 · Jul 7, 2005